



Eric Mou, MD

Postdoctoral Medical Fellow, Oncology

Bio

BIO

I was born in Oregon and raised in Iowa, where I cultivated my initial interest in science and medicine. I completed my undergraduate degree and medical school at the University of Iowa before heading to Stanford University for my internal medicine residency and oncology fellowship training. I chose this field to try my best in assisting patients during times of great need, and working to understand what is of greatest importance to them as they navigate their unique journey of cancer care. My clinical focus is in the care of patients with lymphoma and other hematologic cancers. My scholarly interests include better understanding the efficacy cancer therapeutics, improving patients' experience as they proceed through treatment, and promoting strength in medical education.

HONORS AND AWARDS

- Stanford Hematology and Oncology Fellowship Humanism Award, Stanford University School of Medicine, Divisions of Hematology and Oncology (2020)
- Timothy F. Beckett, Jr. Award for Best Clinical Teaching by a Medicine Fellow, Stanford University School of Medicine, Department of Internal Medicine (2018)
- Award for Best Clinical Teaching by a Medicine Resident, Stanford University School of Medicine, Department of Internal Medicine (2017)
- Charles Dorsey Armstrong Award for Clinical Excellence in Patient Care, Stanford University School of Medicine, Department of Internal Medicine (2017)
- Julian Wolfsohn Award for Outstanding Performance in Internal Medicine, Stanford University School of Medicine, Department of Internal Medicine (2017)
- Medical Student Education Award, Stanford University School of Medicine (2015)
- William R. Wilson Award for Outstanding Performance in Internal Medicine by a Senior Medical Student, Carver College of Medicine, University of Iowa (2014)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Clinical Oncology (2017 - present)
- Member, American Society of Hematology (2016 - present)
- Member, American College of Physicians (2014 - present)

PROFESSIONAL EDUCATION

- Fellowship, Stanford University , Hematology and Oncology (2020)
- Residency, Stanford University , Internal Medicine (2017)
- MD, Carver College of Medicine, University of Iowa (2014)
- BS, University of Iowa , Biomedical Engineering (2010)

Publications

PUBLICATIONS

- **Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study** *BLOOD ADVANCES*
Ruan, J., Chen, Z., Larson, M. C., Bennani, N., Allen, P., Mou, E., Wallace, D., Mehta-Shah, N., Lossos, I. S., Castillo, L., Jaye, D. L., Vega, F., Inghirami, et al
2026; 10 (10): 3480-3493
- **Development and evaluation of a systematic educational intervention for cutaneous lymphoma patients: A pilot study** *PATIENT EDUCATION AND COUNSELING*
Moody, W., Mott, S. L., Abid, R., Mou, E., Liu, V.
2026; 149: 109685
- **Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMP study** *BLOOD*
Feldman, A. L., Dasari, S., Rimsza, L. M., Scott, D. W., Oishi, N., Hu, G., Farinha, P., Amador, C., Campo, E., Chan, W. C., Cook, J. R., Delabie, J., Fu, et al
2026; 147 (11): 1199-1214
- **Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.** *Blood advances*
Wang, Y., Larson, M. C., Hwang, S. R., Villa, D., Kugathasan, L., Kumar, A., Joseph, A., Brooks, T. R., Hill, B. T., Bond, D. A., Maddocks, K. J., Nizamuddin, I. A., Kahl, et al
2025
- **Cutaneous T-cell Lymphoma in Pregnancy and Post-Partum Period: A Systematic Review.** *Journal of the American Academy of Dermatology*
Moody, W., Marti, A. A., Alsawas, M., Mou, E., Prokop, L., Murad, M. H., Liu, V.
2025
- **Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study** *LEUKEMIA & LYMPHOMA*
Toumeh, N., Larson, M., Negaard, B., Casulo, C., Ahmed, S., Maurer, M., Feldman, A., Mou, E., Cohen, J., Habermann, T., Chihara, D., Lossos, I. S., Friedberg, et al
2025: 1-8
- **Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts** *BLOOD CANCER JOURNAL*
Mondello, P., Negaard, B., Feldman, A. L., Link, B. K., Casulo, C., Chihara, D., Russler-Germain, D., Romancik, J., Gribbin, C., Haddadi, S., Mou, E., Micallef, I. N., Johnston, et al
2025; 15 (1): 134
- **Incorporating novel therapies into the treatment of older patients with classic Hodgkin lymphoma.** *Expert review of hematology*
Ravindra, A., Mou, E.
2025: 1-17
- **An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.** *NEJM evidence*
Rodday, A. M., Evens, A. M., Maurer, M. J., Upshaw, J. N., Counsell, N., Rossetti, S., Chang, C., Cui, Z., Xiang, Q., Mwangi, R., Advani, R., Andre, M., Gallamini, et al
2025: EVIDoa2500115
- **The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool** *BLOOD ADVANCES*
Maurer, M. J., Parsons, S. K., Upshaw, J. N., Rodday, A., Mwangi, R., Rossetti, S., Friedberg, J. W., Gallamini, A., Federico, M., Hawkes, E., Hodgson, D., Johnson, P., Link, et al
2025; 9 (6): 1366-1369
- **Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting** *JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY*
Dhakal, P., Sy, M., Sutamtewagul, G., Mou, E., Yu, N., Pemmaraju, N.
2024; 7 (3): 205-209

- **Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.** *American journal of hematology*
Mou, E., Fernandez-Pol, S., Li, S., Rieger, K. E., Novoa, R., Suarez, C. J., Wieland, R., Weng, W., Kim, Y. H., Khodadoust, M. S.
2024
- **Sezary syndrome initially presenting as pityriasis rubra pilaris: Clinicopathologic study of 3 cases.** *JAAD case reports*
Alsawas, M., Alzayadneh, E., Mou, E., Liu, V.
2024; 44: 101-106
- **Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma** *FRONTIERS IN IMMUNOLOGY*
Lefebvre, M. N., Borcherding, N., Reis, R. J., Mou, E., Liu, V., Jabbari, A.
2023; 14: 1228563
- **Small volume biopsy diagnostic yield at initial diagnosis versus recurrence/transformation of follicular lymphoma: Aretrospective Cyto-Heme Interinstitutional Collaborative study.** *Cancer cytopathology*
Fitzpatrick, M. J., Sundaram, V., Ly, A., Abramson, J. S., Balassanian, R., Cheung, M. C., Cook, S. L., Falchi, L., Frank, A. K., Gupta, S., Hasserjian, R. P., Lin, O., Long, et al
2022
- **Diagnostic Discrepancies in Small-volume Biopsy for the Initial Diagnosis, Recurrence, and Transformation of Follicular Lymphoma: A Multi-Institutional Collaborative Study.** *The American journal of surgical pathology*
Volaric, A. K., Lin, O., Balassanian, R., Cook, S., Falchi, L., Fitzpatrick, M. J., Frank, A. K., Gupta, S., Hasserjian, R. P., Long, S., Ly, A., Menke, J. R., Mou, et al
2022
- **The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Rodday, A. M., Parsons, S. K., Upshaw, J. N., Friedberg, J. W., Gallamini, A., Hawkes, E., Hodgson, D., Johnson, P., Link, B. K., Mou, E., Savage, K. J., Zinzani, P. L., Maurer, et al
2022: JCO2202473
- **Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome.** *Blood*
Khodadoust, M. S., Mou, E., Kim, Y. H.
2022
- **Increasing tissue requirements in lymphoma trials may exclude patients with high risk disease or worse prognosis.** *Blood advances*
Desai, S. H., Mwangi, R., Ng, W. L., King, R. L., Maurer, M. J., Cerhan, J. R., Feldman, A., Farooq, U., Mou, E., Habermann, T. M., Thompson, C. A., Wang, Y., Witzig, et al
2022
- **Sequential Pembrolizumab and AVD is Highly Effective at any PD-L1 Expression Level in Untreated Hodgkin Lymphoma.** *Blood advances*
Allen, P. B., Lu, X., Chen, Q., Kane, K. L., Chmiel, J. S., Barnea Slonim, L., Sukhanova, M., Savas, H., Evens, A. M., Advani, R., Pro, B., Karmali, R., Palmer, et al
2022
- **Global Cytopathology-Hematopathology Practice Trends.** *American journal of clinical pathology*
Zadeh, S. L., Balassanian, R., Cheung, M. C., Falchi, L., Hasserjian, R., Lin, O., Long, S. R., Menke, J. R., Mou, E., Natkunam, Y., Ruiz-Cordero, R., Volaric, A. K., Wang, et al
2021
- **Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.** *Blood advances*
Orellana-Noia, V. M., Isaac, K., Malecek, M., Bartlett, N. L., Voorhees, T. J., Grover, N. S., Hwang, S. R., Bennani, N. N., Hu, R., Hill, B. T., Mou, E., Advani, R., Carter, et al
2021
- **Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.** *Leukemia & lymphoma*
Mou, E., Falchi, L., Sundaram, V., Abramson, J. S., Balassanian, R., Beygi, S., Fitzpatrick, M. J., Frank, A. K., Gupta, S., Lin, O., Long, S. R., Menke, J. R., Reed, et al
2021: 1-9
- **A randomized study of a best practice alert for platelet transfusions.** *Vox sanguinis*

Murphy, C., Mou, E., Pang, E., Shieh, L., Hom, J., Shah, N.
2021

- **Hodgkin Lymphoma** *Williams Hematology, 10th ed.*

Spinner, M., Mou, E., Advani, R.
McGraw-Hill.2021

- **Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma.** *Blood*

Allen, P. B., Savas, H. n., Evens, A. M., Advani, R. n., Palmer, B. n., Pro, B. n., Karmali, R. n., Mou, E. n., Bearden, J. n., Dillehay, G. n., Bayer, R. n., Eisner, R. M., Chmiel, et al
2020

- **Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies).** *International journal of radiation oncology, biology, physics*

Mou, E. n., Advani, R. H., von Eyben, R. n., Rosenberg, S. A., Hoppe, R. T.
2020

- **Thrombophilia testing in the inpatient setting: impact of an educational intervention.** *BMC medical informatics and decision making*

Kwang, H. n., Mou, E. n., Richman, I. n., Kumar, A. n., Berube, C. n., Kaimal, R. n., Ahuja, N. n., Harman, S. n., Johnson, T. n., Shah, N. n., Witteles, R. n., Harrington, R. n., Shieh, et al
2019; 19 (1): 167

- **An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting** *JOURNAL OF GENERAL INTERNAL MEDICINE*

Jun, T., Kwang, H., Mou, E., Berube, C., Bentley, J., Shieh, L., Hom, J.
2019; 34 (1): 29-30

- **The Power of Trust** *JAMA ONCOLOGY*

Mou, E., Schapira, L., Kunz, P.
2018; 4 (9): 1173–74

- **Magnitude of Potentially Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting.** *Journal of hospital medicine*

Mou, E. n., Kwang, H. n., Hom, J. n., Shieh, L. n., Kumar, A. n., Richman, I. n., Berube, C. n.
2017; 12 (9): 735–38

PRESENTATIONS

- Embolic Temblor: A Case of Rapidly Progressive RV Failure in a Patient with Severe Pulmonary Hypertension and Metastatic Breast Cancer - American Thoracic Society Annual Meeting, 2016